{"entity":{"id":"ctag1b","kind":"target","name":"CTAG1B","aka":["cancer/testis antigen 1B","Cancer/testis antigen 1","NY-ESO-1","LAGE2B","LAGE2A","ESO1","CT6.1","CTAG1"],"tldr":"CTAG1B (Cancer/testis antigen 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.","summary":"UniProt has no function text for P78358; HGNC names it \"cancer/testis antigen 1B\".\n\nCIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Letetresgene Autoleucel. In OnCo, 1 product record names it (Letetresgene autoleucel).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:2491","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2491"},{"label":"UniProt P78358","url":"https://www.uniprot.org/uniprotkb/P78358/entry"},{"label":"NCBI Gene 1485","url":"https://www.ncbi.nlm.nih.gov/gene/1485"},{"label":"Ensembl ENSG00000184033","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184033"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["letetresgene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07174427"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Myxoid Liposarcoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CTAG1B","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:2491","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2491","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P78358","url":"https://www.uniprot.org/uniprotkb/P78358/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CTAG1B","url":"https://civicdb.org/features/1278","note":"2 evidence items, 0 assertions, 2 variants; diseases: Multiple Myeloma, Myxoid Liposarcoma (GraphQL API, CC0)"}],"specificity":"tumour-associated","distribution":"one-type","specificityNote":"Tumour-associated overexpression: HPA finds the RNA tissue enriched in normal testis, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA CTAG1B: RNA tissue enriched (testis 8 nTPM); high antibody staining in 1 normal tissue; highest cancer staining carcinoid (1 of 4 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Multiple myeloma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas CTAG1B tissue","url":"https://www.proteinatlas.org/ENSG00000184033-CTAG1B/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas CTAG1B pathology","url":"https://www.proteinatlas.org/ENSG00000184033-CTAG1B/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000184033 associations","url":"https://platform.opentargets.org/target/ENSG00000184033/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:2491","ensembl":"ENSG00000184033","uniprot":"P78358","entrez":"1485","firstDescribed":1997,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Chen Y.-T. et al, Proc. Natl. Acad. Sci. U.S.A, 1997, \"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9050879/","biology":"UniProt has no function text for P78358; HGNC names it \"cancer/testis antigen 1B\". Location: Cytoplasm (UniProt). Locus Xq28 (HGNC).","whereFound":["Multiple myeloma: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/ctag1b/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/"}],"trial":[{"id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/"}]}}